Progress on the biomarkers for tuberculosis diagnosis

Critical Reviews in Eukaryotic Gene Expression

Volumn 21, Issue 4, 2011, Pages 379-391

  Fu, Tiwei ^a   Xie, Jianping ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

Biomarker; Diagnosis; Immunology; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

ANTIGEN 85A; ANTIGEN 85B; ANTIGEN 85C; BACTERIAL ANTIGEN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CD11B ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; INTERLEUKIN 2; INTERLEUKIN 4; LIPOARABINOMANNAN; MONOCYTE CHEMOTACTIC PROTEIN 2; NEOPTERIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

ARTICLE; BLOOD ANALYSIS; BREATH ANALYSIS; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HOST PARASITE INTERACTION; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; MASS FRAGMENTOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMEAR; SPUTUM ANALYSIS; T LYMPHOCYTE; TUBERCULOSIS; URINALYSIS;

EID: 83655197562     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v21.i4.70     Document Type: Article

References (72)

1. WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health. 2010 Dec;18(4):237.
2. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006 Nov 4;368(9547):1575-80.
3. Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science. 2010 May 14;328(5980):852-6.
4. Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? Immunol Res. 2011 Aug;50(2-3):202-12.
5. Nahid P, Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc. 2006;3(1):103-10.
6. Lalvani A, Richeldi L, Kunst H. Interferon gamma assays for tuberculosis. Lancet Infect Dis. 2005 Jun;5(6):322-4; author reply 5-7.
7. Guerra RL, Hooper NM, Baker JF, Alborz R, Armstrong DT, Maltas G, Kiehlbauch JA, Dorman SE. Use of the amplified mycobacterium tuberculosis direct test in a public health laboratory: test performance and impact on clinical care. Chest. 2007 Sep;132(3):946-51.
8. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89-95.
9. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol. 2011 May;11(5):343-54.
10. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993 Dec 1;178(6):2249-54.
11. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr Opin Pulm Med. 2009 May;15(3):188-200.
12. Borkowska D, Zwolska Z, Michalowska-Mitczuk D, Kosela MK, Zabost A, Napiorkowska A, Kozinska M, Brzezinska S, Augustynowicz-Kopec E. Interferon-gamma assays T-SPOT.TB for the diagnosis of latent tuberculosis infection. Pneumonol Alergol Pol. 2011;79(4):264-71.
13. Demissie A, Abebe M, Aseffa A, Rook G, Fletcher H, Zumla A, Weldingh K, Brock I, Andersen P, Doherty TM. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol. 2004 Jun 1;172(11):6938-43.
14. Dheda K, Chang JS, Breen RA, Kim LU, Haddock JA, Huggett JF, Johnson MA, Rook GA, Zumla A. In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis. Am J Respir Crit Care Med. 2005 Aug 15;172(4):501-8.
15. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol. 2001 Feb;2(2):123-8.
16. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997 Mar;61(3):246-57.
17. Proost P, Wuyts A, Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol. 1996 Jan;59(1):67-74.
18. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, Eugen-Olsen J, Ravn P. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J. 2008 Dec;32(6):1607-15.
19. Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, Lauria FN, et al. IP-10 detection in urine is associated with lung diseases. BMC Infect Dis. 2010;10:333.
20. Alsleben N, Ruhwald M, Russmann H, Marx FM, Wahn U, Magdorf K. Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: A case-control study. Scand J Infect Dis. Posted online on November 21, 2011
21. Bast RC, Jr., Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998 Oct-Dec;13(4):179-87.
22. Ozsahin SL, Turgut B, Nur N, Dogan OT, Erselcan T, Berk S. Validity of the CA125 level in the differential diagnosis of pulmonary tuberculosis. Jpn J Infect Dis. 2008 Jan;61(1):68-9.
23. Mas MR, Comert B, Saglamkaya U, Yamanel L, Kuzhan O, Ateskan U, Kocabalkan F. CA-125; a new marker for diagnosis and follow-up of patients with tuberculous peritonitis. Dig Liver Dis. 2000 Oct;32(7):595-7.
24. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008 Apr;8(4):247-58.
25. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007 Jul;13(7):843-50.
26. Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, Beyers N, Bolliger CT, van Helden PD, Walzl G. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol. 2006 Aug;145(2):252-60.
27. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jaton K, Faouzi M, Day CL, Hanekom WA, Bart PA, Pantaleo G. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med. 2011 Mar;17(3):372-6.
28. Aung H, Wu M, Johnson JL, Hirsch CS, Toossi Z. Bioactivation of latent transforming growth factor beta1 by Mycobacterium tuberculosis in human mononuclear phagocytes. Scand J Immunol. 2005 Jun;61(6):558-65.
29. Juffermans NP, Dekkers PE, Verbon A, Speelman P, van Deventer SJ, van der Poll T. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun. 2001 Aug;69(8):5182-5.
30. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis. 2007 Jul;11(4):289-99.
31. Le Cabec V, Carreno S, Moisand A, Bordier C, Maridonneau-Parini I. Complement receptor 3 (CD11b/CD18) mediates type I and type II phagocytosis during nonopsonic and opsonic phagocytosis, respectively. J Immunol. 2002 Aug 15;169(4):2003-9.
32. Ghosh S, Saxena RK. Early effect of Mycobacterium tuberculosis infection on Mac-1 and CAM-1 expression on mouse peritoneal macrophages. Exp Mol Med. 2004 Oct 31;36(5):387-95.
33. Demir T, Yalcinoz C, Keskinel I, Demiroz F, Yildirim N. Sicam-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2002 Feb;6(2):155-9.
34. Mukae H, Ashitani J, Tokojima M, Ihi T, Kohno S, Matsukura S. Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis. Respirology. 2003 Sep;8(3):326-31.
35. Kawaguchi H, Ina Y, Ito S, Sato S, Sugiura Y, Tomita H, Ogisu N, Takada K, Yamamoto M, Morishita M, Yoshikawa K. [Serum levels of solubule tumor necrosis factor (TNF) receptors in patients with pulmonary tuberculosis]. Kekkaku. 1996 Mar;71(3):259-65.
36. Ozdemir D, Cesur S, Annakkaya AN, Tarhan G, Hoca NT, Sencan I, Aslan T, Ceyhan I, Balbay O, Guclu E. Serum neopterin concentrations in healthy healthcare workers compared with healthy controls and patients with pulmonary tuberculosis. Med Sci Monit. 2006 Dec;12(12):CR521-4.
37. Djoba Siawaya JF, Bapela NB, Ronacher K, Veenstra H, Kidd M, Gie R, Beyers N, van Helden P, Walzl G. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J Infect. 2008 May;56(5):340-7.
38. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003 Jun;111(12):1805-12.
39. Ito K, Yoshiyama T, Wada M, Ogata H. [C-reactive protein in patients with bacteriological positive lung tuberculosis]. Kekkaku. 2004 Apr;79(4):30-11.
40. Takashima T, Ueta C, Tsuyuguchi I, Kishimoto S. Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis. Infect Immun. 1990 Oct;58(10):3286-92.
41. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. CritCare Med. 1993 Oct;21(10 Suppl):S447-63.
42. Rodrigues DS, Medeiros EA, Weckx LY, Bonnez W, Salomao R, Kallas EG. Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin Exp Immunol. 2002 Apr;128(1):149-54.
43. Paine R, 3rd, Morris SB, Jin H, Baleeiro CE, Wilcoxen SE. ICAM-1 facilitates alveolar macrophage phagocytic activity through effects on migration over the AEC surface. Am J Physiol Lung Cell Mol Physiol. 2002 Jul;283(1):L180-7.
44. Immanuel C, Swamy R, Kannapiran M, Vijayalakshmi S, Sundaram V, Jagannath K, Paramasivan CN. Neopterin as a marker for cell-mediated immunity in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997 Apr;1(2):175-80.
45. Samanich KM, Keen MA, Vissa VD, Harder JD, Spencer JS, Belisle JT, Zolla-Pazner S, Laal S. Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis. Clin Diagn Lab Immunol. 2000 Jul;7(4):662-8.
46. Brock I, Munk ME, Kok-Jensen A, Andersen P. Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis. 2001 May;5(5):462-7.
47. Arend SM, Engelhard AC, Groot G, de Boer K, Andersen P, Ottenhoff TH, van Dissel JT. Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis-specific and nonspecific antigens for detection of latent infection in persons with recent tuberculosis contact. Clin Diagn Lab Immunol. 2001 Nov;8(6):1089-96.
48. Bahk YY, Kim SA, Kim JS, Euh HJ, Bai GH, Cho SN, et al. Antigens secreted from Mycobacterium tuberculosis: identification by proteomics approach and test for diagnostic marker. Proteomics. 2004 Nov;4(11):3299-307.
49. Kunnath-Velayudhan S, Salamon H, Wang HY, Davidow AL, Molina DM, Huynh VT, Cirillo DM, Michel G, Talbot EA, Perkins MD, Felgner PL, Liang X, Gennaro ML. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14703-8.
50. Li Y, Zeng J, Shi J, Wang M, Rao M, Xue C, Du Y, He ZG. A proteome-scale identification of novel antigenic proteins in Mycobacterium tuberculosis toward diagnostic and vaccine development. J Proteome Res. 2010 Sep 3;9(9):4812-22.
51. Wiker HG, Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev. 1992 Dec;56(4):648-61.
52. Desjardin LE, Perkins MD, Wolski K, Haun S, Teixeira L, Chen Y, Johnson JL, Ellner JJ, Dietze R, Bates J, Cave MD, Eisenach KD. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med. 1999 Jul;160(1):203-10.
53. Ramalingam B, Uma Devi KR, Raja A. Isotype-specific anti-38 and 27 kDa (mpt 51) response in pulmonary tuberculosis with human immunodeficiency virus coinfection. Scand J Infect Dis. 2003;35(4):234-9.
54. Singh KK, Dong Y, Belisle JT, Harder J, Arora VK, Laal S. Antigens of Mycobacterium tuberculosis recognized by antibodies during incipient, subclinical tuberculosis. Clin Diagn Lab Immunol. 2005 Feb;12(2):354-8.
55. Kan-Sutton C, Jagannath C, Hunter RL Jr. Trehalose 6,6′-dimycolate on the surface of Mycobacterium tuberculosis modulates surface marker expression for antigen presentation and costimulation in murine macrophages. Microbes Infect. 2009 Jan;11(1):40-8.
56. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen P, Doherty TM. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol. 2006 Feb;13(2):179-86.
57. Kharitonov SA, Barnes PJ. Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers. 2002 Jan-Feb;7(1):1-32.
58. Phillips M, Cataneo RN, Condos R, Ring Erickson GA, Greenberg J, La Bombardi V, Munawar MI, Tietje O. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb). 2007 Jan;87(1):44-52.
59. Syhre M, Chambers ST. The scent of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2008 Jul;88(4):317-23.
60. Syhre M, Manning L, Phuanukoonnon S, Harino P, Chambers ST. The scent of Mycobacterium tuberculosis-part II breath. Tuberculosis (Edinb). 2009 Jul;89(4):263-6.
61. Phillips M, Basa-Dalay V, Bothamley G, Cataneo RN, Lam PK, Natividad MP, Schmitt P, Wai J. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis (Edinb). 2010 Mar;90(2):145-51.
62. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426-37.
63. Thierry D, Brisson-Noel A, Vincent-Levy-Frebault V, Nguyen S, Guesdon JL, Gicquel B. Characterization of a Mycobacterium tuberculosis insertion sequence, IS6110, and its application in diagnosis. J Clin Microbiol. 1990 Dec;28(12):2668-73.
64. Cannas A, Goletti D, Girardi E, Chiacchio T, Calvo L, Cuzzi G, Piacentini M, Melkonyan H, Umansky SR, Lauria FN, Ippolito G, Tomei LD. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2008 Feb;12(2):146-51.
65. Rebollo MJ, San Juan Garrido R, Folgueira D, Palenque E, Diaz-Pedroche C, Lumbreras C, Aguado JM. Blood and urine samples as useful sources for the direct detection of tuberculosis by polymerase chain reaction. Diagn Microbiol Infect Dis. 2006 Oct;56(2):141-6.
66. Boehme C, Molokova E, Minja F, Geis S, Loscher T, Maboko L, Koulchin V, Hoelscher M. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg. 2005 Dec;99(12):893-900.
67. Kim K, Visintin I, Alvero AB, Mor G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med. 2009 Mar;29(1):47-55.
68. Sartain MJ, Slayden RA, Singh KK, Laal S, Belisle JT. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Mol Cell Proteomics. 2006 Nov;5(11):2102-13.
69. Brahmbhatt S, Black GF, Carroll NM, Beyers N, Salker F, Kidd M, Lukey PT, Duncan K, van Helden P, Walzl G. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol. 2006 Nov;146(2):243-52.
70. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2009 Mar;9(3):162-72.
71. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet. 2010 May 29;375(9729):1920-37.
72. Chakera A, Lucas A, Lucas M. Surrogate markers of infection: interrogation of the immune system. Biomark Med. 2011 Apr;5(2):131-48.